Literature DB >> 28775605

THERAPY AND PROPHYLAXIS IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.

Mkk Rao1, R M Gupta2, V C Ohri3.   

Abstract

Entities:  

Keywords:  HIV prophylaxis; HIV therapy

Year:  2017        PMID： 28775605      PMCID： PMC5531845          DOI： 10.1016/S0377-1237(17)30270-8

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN： 0377-1237


× No keyword cloud information.
  21 in total

1.  Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1997-06-25       Impact factor: 56.272

2.  Recommendations on the safe and effective use of short-course ZDV for prevention of mother-to-child transmission of HIV.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1998-10-09

Review 3.  British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee.

Authors: 
Journal:  Lancet       Date:  1997-04-12       Impact factor: 79.321

4.  3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.

Authors:  M H St Clair; C A Richards; T Spector; K J Weinhold; W H Miller; A J Langlois; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 5.  AIDS commentary. Azidothymidine.

Authors:  M S Hirsch
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

6.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  R S Sperling; D E Shapiro; R W Coombs; J A Todd; S A Herman; G D McSherry; M J O'Sullivan; R B Van Dyke; E Jimenez; C Rouzioux; P M Flynn; J L Sullivan
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

7.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

8.  Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.

Authors:  R W Coombs; S L Welles; C Hooper; P S Reichelderfer; R T D'Aquila; A J Japour; V A Johnson; D R Kuritzkes; D D Richman; S Kwok; J Todd; J B Jackson; V DeGruttola; C S Crumpacker; J Kahn
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

Review 9.  Management of antiretroviral therapy.

Authors:  A Gurtman; F Borrego; M E Klotman
Journal:  Semin Nephrol       Date:  1998-07       Impact factor: 5.299

10.  Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery.

Authors:  P J Boyer; M Dillon; M Navaie; A Deveikis; M Keller; S O'Rourke; Y J Bryson
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.